DaVita Inc. (DVA) has been gaining from its business model. The optimism led by a solid fourth-quarter 2023 performance and the acquisition of dialysis centers are expected to contribute further. However, concerns regarding its dependence on commercial payers and macroeconomic challenges persist. Over the past year, this Zacks Rank #1 (Strong Buy) stock has gained 57.8% compared with a 15.7% rise of the industry and 27.4% growth of the S&P 500. The renowned global comprehensive kidney care provider has a ma ...